ArticleObstetrics and gynecology2025
A Feasibility Study for Mapping Ovarian Sentinel Lymph Nodes: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
Article in Obstetrics and gynecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent national trends in pelvic and paraaortic lymphadenectomy in gynecologic oncology fellowship training programs: ACGME data from 2019-2025.Gynecologic oncology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTo evaluate four methods of injecting indocyanine green (ICG) around the adnexa and identify the optimal technique for ovarian sentinel lymph node (SLN) mapping.
methodPatients presenting for management of an adnexal mass were prospectively enrolled. Patients with peritoneal carcinomatosis were excluded. Four injection methods were evaluated: 1) intratubal, 2) paraovarian peritoneum, 3) infundibulopelvic (IP) ligament after resection of the adnexal mass, and 4) IP ligament before resection of the adnexal mass. Two mL of ICG was injected, and at least 10 minutes of transit time was allowed. The ipsilateral and contralateral pelvic and para-aortic lymph node beds were evaluated for ICG uptake. Retroperitoneal nodal resection was performed if indicated. EXPERIENCE: Forty patients were enrolled, 10 in each group. For method 1, 20.0% of SLNs mapped, all to the ipsilateral para-aortic lymph node bed. For method 2, 10.0% mapped, only to the ipsilateral para-aortic lymph node bed. For method 3, 50.0% mapped to the ipsilateral para-aortic lymph node bed (n=3), contralateral para-aortic lymph node bed (n=1), or ipsilateral pelvic lymph node bed (n=1). For method 4, 70.0% mapped to the ipsilateral para-aortic lymph node bed (n=5) or ipsilateral pelvic lymph node bed (n=2). Surgeons reported methods 1 and 2 as cumbersome, and excessive peritoneal staining made SLN identification difficult. No injection-related complications were reported.
conclusionInjection of ICG into the IP ligament before or after adnexal mass resection led to similar rates of SLN mapping and was deemed feasible by surgeons. Only one SLN was identified contralateral to the adnexal mass, and all but three mapped to the para-aortic region. Injection into the IP ligament should be evaluated in patients with likely adnexal malignancy, including SLN resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.